Pyxis Oncology, Inc.

NASDAQ:PYXS

Biotechnology

Healthcare
$1.41 +5.53%

+$0.11 today

Market cap
$168.65M
Beta
1.43
P/E (TTM)
-1.6
EPS (TTM)
-$1.29
52W Low $0.97High $5.55

Volume 0.75M

Average 0.50M

PYXS Interest Income

Income earned on cash, deposits, and investments held by the company.

Pyxis Oncology, Inc.NASDAQ: PYXS

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $457K fell 63.2% year over year, behind the -58.0% change in trailing-twelve-month interest income. Sequentially, it fell 23.8% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.

Context

  • Interest income amounted to 26.0% of revenue in FY2025, down 17.5 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -63.2% toward the trailing-twelve-month pace of -58.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$457K-23.8% QoQ
Last fiscal yearDec 2025
$3.61M-48.7% YoY
LTMMar 2026
$2.83M-58.0% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.2%——
1 year-48.7%——
3-year CAGR+9.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
3.61M USD
Year-over-year change
-48.7%
4-year CAGR
+254.0%

Interest Income vs competitors

How PYXS compares with its peers on the latest reported figures

  • PYXS's LTM Mar 2026 interest income of $2.83M is the 7th highest of the 10 companies compared; the peer median is $5.84M.
  • Its year-over-year change of -58.0% is the 8th highest of 9, against a peer median of -37.7%.
  • Interest income amounts to 20.4% of revenue for PYXS, versus a peer median of 26.5%.
PYXS Competitors Peer median
Interest Income for PYXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$14.02M -40.6%+13.7%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$9.24M -44.8%+81.0%25.3%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$8.9M -24.3%+82.0%12.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.8M -35.9%+15.5%27.6%
ZURAZura Bio LimitedLTM Mar 2026$5.84M -32.1%+2131.8%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.84M -27.6%+11.1%1262.2%
PYXSPyxis Oncology, Inc.LTM Mar 2026$2.83M -58.0%+9.3%20.4%
HUMAHumacyte, Inc.LTM Mar 2026$2.26M -39.6%-0.5%111.9%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$0 —+20.3%0.0%
IMRXImmuneering CorporationLTM Mar 2026-$411.45M -18576.2%+44.2%—
Peer median (excluding PYXS) $5.84M-37.7%+20.3%26.5%

Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00016.15M13.86M
Cost of Revenue000475K2.39M
Gross Profit00015.67M11.47M
Gross Margin———97.1%82.8%
Research & Development51.05M86.13M49.59M58.75M73.7M
Selling, General & Admin18.66M37.35M32.61M25.42M22.19M
Operating Expenses69.72M123.48M82.2M105.13M95.89M
Depreciation & Amortization647K709K1.93M2.98M4.51M
EBITDA(75.33M)(120.01M)(71.86M)(65.51M)(73.72M)
EBITDA Margin———-405.8%-532.0%
Operating Income(69.72M)(123.48M)(82.2M)(89.46M)(84.42M)
Operating Margin———-554.1%-609.2%
Interest Income23K2.76M6.63M7.04M3.61M
Interest Expense00000
Other Income / Expenses(6.26M)2.76M8.41M9.97M6.19M
Income Before Tax(75.98M)(120.72M)(73.79M)(79.5M)(78.24M)
Pre-Tax Margin———-492.4%-564.5%
Income Tax Expense000(2.16M)1.39M
Net Income(75.98M)(120.72M)(73.79M)(77.33M)(79.62M)
Net Margin———-478.9%-574.5%
EPS (Basic)(2.53)(3.57)(1.85)(1.32)(1.28)
EPS (Diluted)(2.53)(3.57)(1.85)(1.32)(1.28)
Weighted Avg Shares32.22M33.03M39.9M58.45M62.14M
Weighted Avg Shares (Diluted)32.22M33.03M39.9M58.45M62.14M

Pyxis Oncology, Inc.

NASDAQ:PYXS

Intrinsic Alpha fair value

Locked

Current Price

$1.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.